CHURC1 Antibody

What is CHURC1 protein and what roles does it play in cellular processes?

CHURC1 (Churchill domain containing 1), also known as C14orf52 or CHCH, is a protein with a calculated molecular weight of 13 kDa. Current research indicates that CHURC1 functions as a transcriptional activator that mediates Fibroblast Growth Factor (FGF) signaling during neural development. Additionally, it plays a role in the regulation of cell movement. Importantly, CHURC1 does not bind DNA by itself, suggesting it works in conjunction with other transcriptional machinery or regulatory proteins . The protein is relatively conserved across species, with mouse and rat orthologs showing 96% and 97% sequence identity to human CHURC1, respectively . Despite its identification, the function of CHURC1 has not been extensively studied, and many aspects of its cellular roles remain to be fully elucidated .

What are the typical reactive species and tissues for CHURC1 antibody detection?

CHURC1 antibodies typically demonstrate reactivity with human, mouse, and rat samples, making them versatile tools for comparative studies across these species . Positive Western blot (WB) detection has been specifically reported in mouse skin tissue, mouse liver tissue, and HeLa cells . For immunohistochemistry (IHC) applications, positive detection has been observed in human brain tissue, human gliomas tissue, and human kidney tissue . This tissue distribution pattern aligns with CHURC1's reported role in neural development and suggests potential functions in other tissue types that warrant further investigation.

Technical Applications and Methodologies

For successful immunohistochemical detection of CHURC1 in fixed tissues, appropriate antigen retrieval is critical. The primary recommended method is antigen retrieval with TE buffer at pH 9.0 . Alternatively, antigen retrieval may be performed with citrate buffer at pH 6.0, though this is considered a secondary option . The choice between these methods may depend on tissue type, fixation method, and specific experimental goals. Researchers should consider evaluating both retrieval methods side-by-side when establishing a new IHC protocol for CHURC1 detection, as optimal conditions may vary by tissue type and fixation parameters.

How should I validate CHURC1 antibody specificity in my experimental system?

Validating antibody specificity is crucial for generating reliable research data. For CHURC1 antibody validation, consider implementing the following comprehensive approach:

• Western blot analysis: Verify detection of a single band at the expected molecular weight (13 kDa for CHURC1) . Multiple bands may indicate non-specific binding or protein isoforms.

• Positive and negative controls: Include tissues known to express CHURC1 (e.g., mouse liver tissue, human brain tissue) as positive controls . Consider using tissues with expected low expression or cell lines with CHURC1 knockdown as negative controls.

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide before application to your samples. This should significantly reduce or eliminate specific staining.

• Cross-validation with multiple antibodies: When possible, compare results using antibodies from different sources or those targeting different epitopes of CHURC1.

• Genetic validation: If available, compare detection in wild-type versus CHURC1 knockout or knockdown models to confirm specificity.

This systematic validation approach ensures confidence in subsequent experimental results and addresses potential concerns about antibody cross-reactivity.

What are the critical considerations for designing experiments to study CHURC1's role in FGF signaling?

Given CHURC1's reported role in mediating FGF signaling during neural development , experiments investigating this function require careful design:

• Cell model selection: Choose cell models relevant to neural development (e.g., neural progenitor cells, neuroblastoma cell lines) that express both CHURC1 and FGF pathway components.

• Pathway manipulation: Design experiments that modulate FGF signaling (through ligand addition, receptor inhibition, or downstream pathway perturbation) and assess changes in CHURC1 expression, localization, or post-translational modifications.

• Co-immunoprecipitation studies: Identify potential protein interaction partners within the FGF signaling cascade using CHURC1 antibody for immunoprecipitation followed by mass spectrometry or targeted Western blot analysis.

• Functional readouts: Establish clear phenotypic readouts related to neural development (e.g., cell differentiation markers, migration assays) to assess the functional impact of CHURC1 manipulation.

• Temporal considerations: Given developmental roles, consider time-course experiments that capture dynamic changes in CHURC1 function during differentiation or in response to FGF stimulation.

These design considerations will help elucidate CHURC1's specific mechanisms within FGF signaling pathways and its broader role in neural development.

How should I optimize Western blot protocols for CHURC1 detection?

Optimizing Western blot protocols for the relatively small (13 kDa) CHURC1 protein requires specific technical considerations:

• Gel selection: Use higher percentage (12-15%) SDS-PAGE gels to effectively resolve low molecular weight proteins.

• Transfer conditions: Optimize transfer conditions for small proteins, potentially using higher methanol concentrations in transfer buffer and shorter transfer times to prevent small proteins from passing through the membrane.

• Blocking optimization: Test different blocking reagents (BSA vs. non-fat milk) as some small proteins may be obscured by certain blocking agents.

• Antibody dilution: Begin with the manufacturer's recommended range (1:200-1:1000) and adjust based on signal intensity and background levels.

• Signal enhancement: Consider using signal enhancement systems for detecting low abundance targets, being careful to maintain specificity.

• Loading controls: Select appropriate loading controls within a similar molecular weight range to CHURC1 to ensure comparable transfer efficiency.

These optimization steps should be documented systematically to establish a reliable and reproducible protocol for CHURC1 detection in your specific sample types.

What are the optimal storage conditions to maintain CHURC1 antibody activity?

Maintaining antibody stability and activity requires specific storage conditions. For CHURC1 antibodies, the following conditions are recommended:

Proper storage significantly impacts experimental reproducibility and reduces the need for frequent re-optimization of assay conditions.

How can I apply CHURC1 antibody in studying potential roles in cell movement regulation?

CHURC1 has been identified as playing a role in cell movement regulation , an important process in development, wound healing, and cancer progression. To investigate this function:

• Live-cell imaging: Combine CHURC1 immunocytochemistry with live-cell imaging techniques to correlate CHURC1 expression or localization patterns with cellular migration behaviors.

• Migration assays: Implement scratch assays, transwell migration assays, or chemotaxis chambers to quantitatively assess how CHURC1 perturbation (knockdown, overexpression) affects cellular movement parameters.

• Cytoskeletal co-localization: Perform dual immunofluorescence staining for CHURC1 and cytoskeletal markers (actin, tubulin, focal adhesion proteins) to investigate potential direct interactions with the cell motility machinery.

• Pathway analysis: Examine how CHURC1 manipulation affects established cell movement pathways (Rho GTPases, WASP/WAVE complexes, etc.) using phosphorylation-specific antibodies and activity assays.

• Context-dependent studies: Compare CHURC1's role in normal versus pathological migration (e.g., cancer cell invasion models), as functions may differ based on cellular context.

These approaches will help delineate whether CHURC1 directly modulates cytoskeletal dynamics or indirectly regulates migration through transcriptional mechanisms.

What approaches should I consider when investigating CHURC1's potential roles in disease processes?

While CHURC1's functions are still being elucidated, investigating its potential roles in disease processes requires multifaceted approaches:

• Expression analysis: Utilize CHURC1 antibodies for IHC or Western blot analysis comparing expression levels between normal and pathological tissues, particularly focusing on brain tissues and gliomas where positive detection has been reported .

• Correlation studies: Analyze potential correlations between CHURC1 expression levels and disease progression, patient outcomes, or response to treatments in available tissue repositories or public databases.

• Functional studies: Design in vitro experiments manipulating CHURC1 expression in relevant cell models to assess impacts on disease-related phenotypes (proliferation, invasion, resistance to therapy).

• Mechanistic investigation: Explore how CHURC1's reported roles in FGF signaling and cell movement might contribute to specific pathological processes, particularly in developmental disorders and cancers where these processes are dysregulated.

• Therapeutic potential: Assess whether targeting CHURC1 or its interacting partners might represent a novel therapeutic approach for conditions where it contributes to pathology.

This comprehensive approach can provide insights into CHURC1's potential involvement in disease mechanisms and identify new research directions.

What are common problems when working with CHURC1 antibody and how can they be resolved?

Researchers may encounter several challenges when working with CHURC1 antibody. Here are common issues and their solutions:

• Weak or no signal in Western blot:

  • Increase antibody concentration within recommended range (1:200-1:1000)

  • Extend primary antibody incubation time or temperature

  • Optimize protein loading (increase amount for low abundance targets)

  • Ensure transfer efficiency is appropriate for small proteins (13 kDa)

  • Verify sample integrity and preparation method

• High background in immunohistochemistry:

  • Dilute antibody further within recommended range (1:20-1:200)

  • Optimize blocking conditions (concentration, duration, blocking agent)

  • Increase washing steps duration and number

  • Ensure proper antigen retrieval (test both recommended methods: TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Reduce substrate development time

• Non-specific bands in Western blot:

  • Use freshly prepared samples and prevent protein degradation

  • Optimize blocking conditions

  • Increase stringency of wash steps

  • Consider alternative antibody clones if available

  • Perform peptide competition assay to identify specific bands

• Inconsistent results between experiments:

  • Standardize all protocol parameters (incubation times, temperatures, reagent concentrations)

  • Maintain consistent sample preparation methods

  • Use positive controls with each experiment

  • Monitor antibody storage conditions and avoid repeated freeze/thaw cycles

  • Prepare fresh working dilutions for each experiment

Systematic troubleshooting with proper controls will help identify the specific issues affecting your experiments.

How can I differentiate between specific and non-specific binding when using CHURC1 antibody?

Differentiating between specific and non-specific binding is crucial for accurate data interpretation:

• Molecular weight verification: CHURC1 should appear as a 13 kDa band in Western blot applications . Bands at significantly different molecular weights may represent non-specific binding or cross-reactivity.

• Peptide competition: Pre-incubating the antibody with excess immunizing peptide should eliminate specific binding while leaving non-specific interactions intact. The sequence used for immunogen production includes: "GDCVEKEYPN RGNTCLENGS FLLNFTGCAV CSKRDFMLIT NKSLKEEDGE EIVTYDHLCK NCHHVIARHE YTFSIMDEFQ EYTMLCLLCG KAEDTISILP DDP" .

• Multiple antibody validation: Compare staining patterns using antibodies targeting different epitopes of CHURC1 or from different manufacturers. Consistent patterns suggest specific binding.

• Genetic approaches: Use RNA interference or CRISPR-Cas9 to reduce CHURC1 expression and confirm corresponding reduction in antibody signal.

• Tissue specificity: Compare antibody reactivity across tissues with known expression patterns of CHURC1. Signals should correlate with expected expression levels, with positive detection reported in human brain tissue, human gliomas tissue, human kidney tissue, mouse skin tissue, and mouse liver tissue .

These complementary approaches provide robust validation of antibody specificity and ensure accurate interpretation of experimental results.

How might CHURC1 antibodies be applied in single-cell analysis techniques?

As single-cell technologies revolutionize biological research, CHURC1 antibodies can be incorporated into these emerging approaches:

• Single-cell Western blot: Optimize CHURC1 antibody protocols for microfluidic single-cell Western blot platforms to analyze protein expression heterogeneity within populations.

• Mass cytometry (CyTOF): Develop metal-conjugated CHURC1 antibodies for inclusion in multi-parameter mass cytometry panels to correlate CHURC1 expression with cellular phenotypes and other signaling proteins.

• Imaging mass cytometry: Apply metal-labeled CHURC1 antibodies for high-dimensional spatial analysis of protein expression in tissue sections, providing insights into tissue-level heterogeneity.

• Proximity ligation assays: Combine CHURC1 antibodies with antibodies against potential interaction partners for in situ detection of protein-protein interactions at the single-cell level.

• CODEX multiplexed imaging: Incorporate CHURC1 antibodies into highly multiplexed imaging panels to analyze spatial relationships with dozens of other proteins simultaneously.

These advanced applications can reveal cell-type specific functions and expression patterns that might be obscured in bulk analyses, potentially uncovering new aspects of CHURC1 biology.

What are potential future directions for investigating CHURC1's role beyond neural development?

While CHURC1 has been primarily studied in the context of neural development and FGF signaling , several promising research directions warrant investigation:

• Cancer biology: Given its positive detection in gliomas and roles in cell movement , investigate CHURC1's potential contributions to cancer progression, particularly in tumors with aberrant FGF signaling.

• Regenerative medicine: Explore CHURC1's functions in tissue regeneration contexts, particularly in tissues where FGF signaling plays key roles in repair processes.

• Stem cell biology: Examine CHURC1's potential roles in maintaining stemness or directing differentiation in various stem cell populations beyond neural lineages.

• Metabolism: Investigate potential connections between CHURC1 and metabolic regulation, given its detection in metabolically active tissues like liver .

• Immune system: Study possible functions in immune cell development or function, particularly in contexts where migration and FGF signaling intersect with immune processes.

These investigations may reveal broader biological roles for CHURC1 and potentially identify new therapeutic targets for various conditions.